Li, Songye http://orcid.org/0000-0002-6096-8756
Naganawa, Mika
Pracitto, Richard
Najafzadeh, Soheila
Holden, Daniel
Henry, Shannan
Matuskey, David
Emery, Paul R.
Cai, Zhengxin
Ropchan, Jim
Nabulsi, Nabeel
Carson, Richard E.
Huang, Yiyun
Funding for this research was provided by:
National Institute on Aging (R01AG052560, R01AG065474)
Michael J. Fox Foundation for Parkinson's Research
Article History
Received: 15 July 2020
Accepted: 6 December 2020
First Online: 8 January 2021
Compliance with ethical standards
:
: The radioligand [<sup>18</sup>F]SynVesT-1 (formerly referred to as [<sup>18</sup>F]SDM-8) is contained in the international patent application PCT/US2018/018388, Radiolabeled Pharmaceuticals and Methods of Making and Using Same, filed on February 15, 2018 (Inventors: YH, ZC, SL, NN, and REC). The other authors declare that they have no conflict of interest.
: PET imaging experiments were performed in rhesus monkeys (<i>Macaca mulatta</i>) according to a protocol approved by the Yale University Institutional Animal Care and Use Committee. All applicable international, national, and institutional guidelines for the care and use of animals were followed.The study protocol involving human participants was approved by the Yale Human Investigation Committee, the Yale-New Haven Hospital Radiation Safety Committee, and the Yale University Radiation Safety Committee. Study procedures were performed in accordance with federal guidelines and regulations of the United States for the protection of human research subjects contained in Title 45 Part 46 of the Code of Federal Regulations (45 CFR 46).
: Informed consent was obtained from all individual participants included in the study.